Trials / Completed
CompletedNCT02320773
A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice
Non-Interventional Study Assessing Quality of Life, Treatment Satisfaction, Resource Utilisation, and Persistence With Treatment in Overactive Bladder (OAB) Patients Prescribed Betmiga® - A Multicenter Non-interventional Post Authorisation Study (PAS)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 863 (actual)
- Sponsor
- Astellas Pharma Europe Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A study to understand the impact of Betmiga® on patients quality of life, satisfaction with treatment, how long patients remain on treatment, patterns of healthcare resource utilisation, and safety as prescribed by the physicians in routine clinical practice.
Detailed description
Single arm, hybrid model study, observing patients on Betmiga under conditions of routine clinical practice, with some element of retrospective data collection 2 years prior to enrolment of the study
Conditions
- Urgency Incontinence
- Urinary Bladder Overactive
- Overactive Bladder
- Urologic Diseases
- Urinary Bladder Diseases
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Betmiga® | Oral |
Timeline
- Start date
- 2014-11-25
- Primary completion
- 2016-07-27
- Completion
- 2016-07-27
- First posted
- 2014-12-19
- Last updated
- 2024-10-31
Locations
60 sites across 8 countries: Czechia, Denmark, Greece, Ireland, Slovakia, Spain, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT02320773. Inclusion in this directory is not an endorsement.